Citizens JMP lowered the firm’s price target on Bicycle Therapeutics (BCYC) to $10 from $22 and keeps an Outperform rating on the shares. Bicycle recently reported Q2 financial results and updated corporate milestones, and Citizens believes that the main value-driving event for this year is the selection of the optimal go-forward dose of zelenectide pevedotin in the pivotal Duravelo-2 trial. Bicycle shares may still provide upside from current levels, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCYC:
- Bicycle Therapeutics Reports Q2 2025 Financial Results
- Bicycle Therapeutics price target raised to $27 from $25 at RBC Capital
- Bicycle Therapeutics price target lowered to $44 from $48 at Oppenheimer
- Bicycle Therapeutics: Strategic Restructuring and Promising Pipeline Drive Buy Rating
- Bicycle Therapeutics files $500M mixed securities shelf